Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Immuneering Corp Cl A (IMRX)

Immuneering Corp Cl A (IMRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 49,680
  • Shares Outstanding, K 31,050
  • Annual Sales, $ 0 K
  • Annual Income, $ -53,470 K
  • EBIT $ -62 M
  • EBITDA $ -62 M
  • 60-Month Beta -0.32
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.79

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.48
  • Number of Estimates 2
  • High Estimate -0.41
  • Low Estimate -0.54
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4000 +14.29%
on 03/04/25
1.8900 -15.34%
on 02/18/25
-0.2600 (-13.98%)
since 02/14/25
3-Month
1.4000 +14.29%
on 03/04/25
3.8000 -57.89%
on 01/07/25
-0.0350 (-2.14%)
since 12/13/24
52-Week
1.0000 +60.00%
on 08/16/24
3.8300 -58.22%
on 09/16/24
-1.3000 (-44.83%)
since 03/14/24

Most Recent Stories

More News
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)

IMRX : 1.6000 (+3.90%)
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

IMRX : 1.6000 (+3.90%)
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer

IMRX : 1.6000 (+3.90%)
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

IMRX : 1.6000 (+3.90%)
Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024

Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments.

CERO : 1.0200 (+6.23%)
NKGN : 0.1698 (-12.88%)
IMRX : 1.6000 (+3.90%)
AZTR : 0.3569 (+2.91%)
PBM : 0.7839 (+3.19%)
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

/CNW/ -- USA News Group News Commentary – Recent advancements in cancer treatment continue to underscore the transformative potential of innovative therapies...

ONCY : 0.6250 (+0.32%)
RPTX : 1.1000 (-1.79%)
IMRX : 1.6000 (+3.90%)
ONC.TO : 0.91 (unch)
RNXT : 0.9858 (-3.35%)
CRGX : 4.21 (+1.94%)
Immuneering Corporation Forms Pancreatic Cancer Advisory Board to Advance IMM-1-104 Development

Immuneering Corporation establishes a Pancreatic Cancer Advisory Board to enhance clinical guidance for its lead candidate, IMM-1-104.Quiver AI SummaryImmuneering Corporation has established a Pancreatic...

IMRX : 1.6000 (+3.90%)
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Despite significant advances in oncology research, challenges remain as the American Cancer Society...

ONCY : 0.6250 (+0.32%)
PYXS : 1.1100 (+3.74%)
RPTX : 1.1000 (-1.79%)
IMRX : 1.6000 (+3.90%)
CVM : 0.3040 (+0.66%)
ONC.TO : 0.91 (unch)
Immuneering Launches Pancreatic Cancer Advisory Board

IMRX : 1.6000 (+3.90%)
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

IMRX : 1.6000 (+3.90%)

Business Summary

Immuneering Corporation is a biopharmaceutical company advancing a pipeline of oncology and neuroscience product candidates. The company's product candidate includes IMM-1-104. Immuneering Corporation is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 1.7533
2nd Resistance Point 1.7067
1st Resistance Point 1.6533
Last Price 1.6000
1st Support Level 1.5533
2nd Support Level 1.5067
3rd Support Level 1.4533

See More

52-Week High 3.8300
Fibonacci 61.8% 2.7489
Fibonacci 50% 2.4150
Fibonacci 38.2% 2.0811
Last Price 1.6000
52-Week Low 1.0000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar